Introduction

Helicobacter pylori infection causes chronic gastritis, which can progress to severe gastroduodenal pathologies, including peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma. HP is usually transmitted in childhood and persists for life if untreated. The infection affects around half of the population in the world but prevalence varies according to location and sanitation standards. HP has unique properties to colonize gastric epithelium in an acidic environment. The pathophysiology of HP infection is dependent on complex bacterial virulence mechanisms and their interaction with the host immune system and environmental factors, resulting in distinct gastritis phenotypes that determine possible progression to different gastroduodenal pathologies. The causative role of HP infection in gastric cancer development presents the opportunity for preventive screen-and-treat strategies. Invasive, endoscopy-based and non-invasive methods, including breath, stool and serological tests, are used in the diagnosis of HP infection. Their use depends on the specific individual patient history and local availability. HP treatment consists of a strong acid suppressant in various combinations with antibiotics and/or bismuth. The dramatic increase in resistance to key antibiotics used in HP eradication demands antibiotic susceptibility testing, surveillance of resistance and antibiotic stewardship.

This kit is designed with specific primers and probes targeting the conserved region of HP species, generating fluorescence signals on a constant temperature nucleic acid amplification instrument. By employing endpoint detection, it realizes qualitative and genotypic identification of HP at the nucleic acid level.